看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
4 B8 H/ {3 l4 O8 F3 T" Z, A% l9 p" t2 z8 g$ p
" s- S. V/ t* B' \
Currently available feasibility data for possible combination strategies. 2 V$ n( g1 e: |+ M+ y& u
————————————————————————————————
# Q' i) H/ }0 w6 g# P- BCombination Feasibility according to preliminary data ( L+ I# w4 h. v$ _+ K
——————————————————————————————————* w$ c7 A5 Q8 s) ?1 m% B
Bevacizumab + sorafenib Yes, reduced dose
3 [/ n9 E5 C, l% v1 K3 tBevacizumab + sunitinib† No
2 k% A! V2 y1 k rBevacizumab + temsirolimus Yes 4 \7 F1 x5 Y1 K- N
Bevacizumab + everolimus Yes
2 O) V% l W& J: @Sorafenib + sunitinib ? 6 O' c- C- m9 g7 L) N" u6 I R
Sorafenib + temsirolimus Yes, reduced dose
, O8 ^# M" v7 |% ASorafenib + everolimus Yes, reduced dose 3 k q$ ~5 W) [ l" s0 |
Sunitinib + temsirolimus† No ! k8 I( W8 ?8 Y1 q4 A; `/ k
Sunitinib + everolimus ?
1 u" Q$ V& u# U% Z4 XTemsirolimus + everolimus ? 6 J! C; p' ]; I7 S
————————————————————
0 l9 [, C+ f+ J# G8 S$ Z$ b0 H†Led to US FDA warning." K0 j+ @( V2 k$ C1 O$ {7 f* f3 x
?: As yet unattempted combination.6 f4 W- }" {1 `/ t' d! Z6 X: n
|
显身卡
2 Q0 W* t4 j* r. j( k" u t, x: V& \
